Related Experiment Video
Updated: Jul 9, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for
Carina M Mathey1, Martin Coenen2, Ingolf Cascorbi3
1University Hospital Bonn Institute of Human Genetics Venusberg-Campus 1, Gebäude 76 53127 Bonn Germany.
Summary
Polygenic risk scores (PRS) can improve drug response prediction by analyzing multiple genes. Further validation is needed for clinical use in precision medicine.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Inter-individual variability in drug response is a significant clinical challenge.
- Current pharmacogenetics primarily focuses on single-gene variants, while many drug responses are polygenic.
- Genome-wide association studies (GWAS) increasingly support polygenic models for drug response phenotypes.
Purpose of the Study:
- To review the current status and challenges of polygenic risk scores (PRS) in pharmacogenomics (PGx-PRS).
- To explore the potential applications and limitations of PGx-PRS in various clinical settings.
- To outline requirements for the clinical implementation of PGx-PRS.
Main Methods:
- Literature review summarizing the current state of pharmacogenomic polygenic risk scores.
- Analysis of key challenges including cohort size, phenotype definition, and ancestry.
- Discussion of current applications in cardiovascular, psychiatric, and oncological fields.
Main Results:
- PGx-PRS offer a framework for risk stratification beyond monogenic models by capturing cumulative genetic effects.
- Key challenges include limited drug-exposed cohorts, heterogeneous phenotypes, ancestry-related portability issues, and underrepresentation of complex genes like CYP2D6.
- Emerging potential for benefit-risk stratification in cardiovascular, psychiatric, and oncological settings, though validation for routine care is insufficient.
Conclusions:
- Clinical implementation requires standardized methods, multi-ancestry validation, and integration with rare variants in ADME genes.
- Clearer regulatory pathways are necessary for widespread adoption.
- PGx-PRS hold promise as tools for precision prescribing and drug development with future advancements.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...